RELMADA THERAPEUTICS INC's ticker is RLMD and the CUSIP is 75955J402. A total of 118 filers reported holding RELMADA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,557,585 | -16.7% | 519,195 | -31.7% | 0.00% | – |
| Q2 2023 | $1,870,816 | +2.0% | 760,494 | -6.3% | 0.00% | – |
| Q1 2023 | $1,834,742 | -13.4% | 811,833 | +33.8% | 0.00% | – |
| Q4 2022 | $2,117,787 | -97.0% | 606,816 | -67.7% | 0.00% | -100.0% |
| Q3 2022 | $69,468,000 | +203.6% | 1,876,504 | +55.8% | 0.02% | +128.6% |
| Q2 2022 | $22,880,000 | -17.9% | 1,204,813 | +16.6% | 0.01% | +40.0% |
| Q1 2022 | $27,885,000 | +260.3% | 1,033,172 | +200.8% | 0.01% | +400.0% |
| Q4 2021 | $7,739,000 | -34.9% | 343,454 | -24.3% | 0.00% | -50.0% |
| Q3 2021 | $11,895,000 | -7.9% | 453,852 | +12.5% | 0.00% | -33.3% |
| Q2 2021 | $12,909,000 | +618.0% | 403,283 | +689.8% | 0.00% | – |
| Q1 2021 | $1,798,000 | +150.1% | 51,061 | +127.8% | 0.00% | – |
| Q4 2020 | $719,000 | -3.0% | 22,419 | +13.8% | 0.00% | – |
| Q3 2020 | $741,000 | -93.2% | 19,700 | -93.8% | 0.00% | -100.0% |
| Q1 2020 | $10,918,000 | +249.3% | 320,072 | +299.3% | 0.01% | +400.0% |
| Q4 2019 | $3,126,000 | – | 80,166 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,270,072 | $61,269,000 | 9.93% |
| GREAT POINT PARTNERS LLC | 790,000 | $21,322,000 | 5.15% |
| ACUTA CAPITAL PARTNERS, LLC | 342,000 | $9,231,000 | 4.31% |
| COWEN AND COMPANY, LLC | 1,164,361 | $31,426,000 | 3.02% |
| Altium Capital Management LP | 206,000 | $5,560,000 | 1.86% |
| BVF INC/IL | 1,647,400 | $44,463,000 | 1.78% |
| RTW INVESTMENTS, LP | 2,540,074 | $68,557,000 | 1.42% |
| Vivo Capital, LLC | 705,882 | $19,052,000 | 1.31% |
| RA Capital Management | 2,000,000 | $53,980,000 | 1.18% |
| SPHERA FUNDS MANAGEMENT LTD. | 291,252 | $7,861,000 | 1.11% |